Novartis CEO Says Trump Discussed Pricing With Drug CEOs

The video discusses the concept of reducing drug prices through performance-based pricing in the pharmaceutical industry. It highlights the example of Entresto, a drug for heart failure, which has shown to reduce hospitalizations by 20%. The discussion includes the potential savings for the healthcare system and the shift towards outcomes-based contracts. Regulatory challenges are addressed, and the current implementation of such contracts in the US and Europe is explored. The video concludes with a positive outlook on the future of performance-based pricing.

What is the significance of the 20% reduction in hospitalization mentioned in the text?

How are companies like Novartis adapting to performance-based pricing in the current market?